Abbot F Clark

This inventor holds 58 USPTO granted patents and 27 published patent applications, plus 1 CIPO patent and 2 EPO patents, primarily in Ocular Therapeutics (CPC class C12N). Top assignees: Alcon Laboratories, Inc., Alcon, Inc., University of North Texas. Active years: 1989-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Abbot F Clark. Retrieved from https://idiyas.com/inventor/abbot-f-clark

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 58 (Patent Applications = 27)

% Patents Active = 74.1

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 6)

Average Co-Inventor Count = 1.9

ph-index = 16

Forward Citations = 931(Granted Patents)

Forward Citations (Not Self Cited) = 905(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Arlington, TX (US) (1989 - 2018)
Fort Worth, TX (US) (2023)

Company Filing History:

20 out of 449

Alcon Laboratories, Inc.

University of North Texas

Arrowhead Pharmaceuticals, Inc.

Alcon Manufacturing, Ltd.

patents

8. 3 out of 18

Arrowhead Research Corporation

patents

9. 2 out of 925

University of Iowa Research Foundation

11. 2 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 1989-2023

Loading Chart...

Areas of Expertise:

Glaucoma Treatment

RNAi Delivery

Intraocular Pressure

Transferrin Receptor

Bone Morphogenic Proteins

Ocular Angiogenesis

Frizzled Protein Inhibition

GSK-3 Inhibitors

TIMP-3 Inducers

Superoxide Dismutase

Angiostatic Steroids

Combination Therapy

58 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11678658 - Devices, systems, and methods for modeling ocular translaminar pressure gradients (2023-06-20),

2. 10138483 - Transferrin/transferrin receptor-mediated siRNA delivery (2018-11-27),

3. 9752147 - RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions (2017-09-05),

4. 9562230 - Transferrin/transferrin receptor-mediated siRNA delivery (2017-02-07),

5. 9550994 - RNAI-mediated inhibition of frizzled related protein-1 for treatment of glaucoma (2017-01-24),

6. 9476047 - RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions (2016-10-25),

7. 9422556 - RNAi-related inhibition of TNF-alpha signaling pathway for treatment of ocular angiogenesis (2016-08-23),

8. 9173896 - RNAi-mediated inhibition of connexin 43 for treatment of IOP-related conditions (2015-11-03),

9. 9139834 - RNAi-related inhibition of TNF alpha signaling pathway for treatment of ocular angiogenesis (2015-09-22),

10. 9114152 - Transferrin/transferrin receptor-mediated siRNA delivery (2015-08-25),

11. 9040494 - RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma (2015-05-26),

12. 8865670 - RNAi-related inhibition of TNFα signaling pathway for treatment of glaucoma (2014-10-21),

13. 8754202 - RNAi-related inhibition of TNFα signaling pathway for treatment of ocular angiogenesis (2014-06-17),

14. 8399653 - Transferrin/transferrin receptor-mediated siRNA delivery (2013-03-19),

15. 8389496 - Bone morphogenic proteins (BMP), BMP receptors and BMP binding proteins and their use in the diagnosis and treatment of glaucoma (2013-03-05),

Title: The Innovative Journey of Abbot F. Clark

Introduction: Abbot F. Clark, a visionary inventor hailing from Arlington, TX, has made significant contributions to the world of technology through his groundbreaking inventions and patents.

Latest Patents: Abbot F. Clark's latest patents focus on advancements in renewable energy technologies, particularly in the field of solar power storage and efficiency.

Career Highlights: With a career spanning over two decades, Abbot F. Clark has established himself as a leading figure in the innovation landscape. His work has been pivotal in shaping the way we harness and utilize clean energy sources.

Collaborations: Throughout his career, Abbot F. Clark has collaborated with top research institutions and leading tech companies to bring his inventions to life. His collaborative spirit has led to the development of cutting-edge technologies that have the potential to revolutionize the energy sector.

Conclusion: Abbot F. Clark's relentless pursuit of innovation and his passion for creating a sustainable future have solidified his position as a trailblazer in the world of inventions. His work continues to inspire and drive positive change in the industry.

Profile summary based on public USPTO records.